These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15551047)

  • 1. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
    Schjoedt KJ; Andersen S; Rossing P; Tarnow L; Parving HH
    Diabetologia; 2004 Nov; 47(11):1936-9. PubMed ID: 15551047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
    Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Diabetes Care; 2003 May; 26(5):1501-6. PubMed ID: 12716812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
    Dragović T; Ajdinović B; Hrvacević R; Ilić V; Magić Z; Andelković Z; Kocev N
    Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
    Andersen S; van Nieuwenhoven FA; Tarnow L; Rossing P; Rossing K; Wieten L; Goldschmeding R; Parving HH
    Kidney Int; 2005 Jun; 67(6):2325-9. PubMed ID: 15882275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
    Holtkamp FA; de Zeeuw D; Thomas MC; Cooper ME; de Graeff PA; Hillege HJ; Parving HH; Brenner BM; Shahinfar S; Lambers Heerspink HJ
    Kidney Int; 2011 Aug; 80(3):282-7. PubMed ID: 21451458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
    Andersen S; Jacobsen P; Tarnow L; Rossing P; Juhl TR; Parving HH
    Nephrol Dial Transplant; 2003 Feb; 18(2):293-7. PubMed ID: 12543883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
    Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
    J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.
    Crepaldi G; Carta Q; Deferrari G; Mangili R; Navalesi R; Santeusanio F; Spalluto A; Vanasia A; Villa GM; Nosadini R
    Diabetes Care; 1998 Jan; 21(1):104-10. PubMed ID: 9538979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.
    Rossing P; Hommel E; Smidt UM; Parving HH
    Diabetologia; 1994 May; 37(5):511-6. PubMed ID: 8056190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal functional reserve in IDDM patients.
    Sackmann H; Tran-Van T; Tack I; Hanaire-Broutin H; Tauber JP; Ader JL
    Diabetologia; 1998 Jan; 41(1):86-93. PubMed ID: 9498635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes.
    Thomson HJ; Ekinci EI; Radcliffe NJ; Seah JM; MacIsaac RJ; Jerums G; Premaratne E
    J Diabetes Complications; 2016 Mar; 30(2):256-61. PubMed ID: 26794645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Kidney Int; 2002 Jul; 62(1):192-8. PubMed ID: 12081578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.